Previous Article | Next Article 
Journal of Virology, May 2000, p. 4017-4027, Vol. 74, No. 9
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Evidence for Viral Virulence as a Predominant
Factor Limiting Human Immunodeficiency Virus Vaccine Efficacy
Petra
Mooij,1
Willy M. J. M.
Bogers,1
Herman
Oostermeijer,1
Wim
Koornstra,1
Peter J. F.
Ten Haaft,1
Babs E.
Verstrepen,1
Gert
Van Der
Auwera,2 and
Jonathan L.
Heeney1,*
Department of Virology, Biomedical Primate
Research Center, 2280 GH Rijswijk, The
Netherlands,1 and Department of
Microbiology, Institute of Tropical Medicine, B2000 Antwerp,
Belgium2
Received 30 April 1999/Accepted 21 January 2000
Current strategies in human immunodeficiency virus type 1 (HIV-1)
vaccine development are often based on the production of different
vaccine antigens according to particular genetic clades of HIV-1
variants. To determine if virus virulence or genetic distance had a
greater impact on HIV-1 vaccine efficacy, we designed a series of
heterologous chimeric simian/human immunodeficiency virus (SHIV)
challenge experiments in HIV-1 subunit-vaccinated rhesus macaques. Of a
total of 22 animals, 10 nonimmunized animals served as controls; the
remainder were vaccinated with the CCR5 binding envelope of
HIV-1W6.1D. In the first study, heterologous challenge
included two nonpathogenic SHIV chimeras encoding the envelopes of the
divergent clade B HIV-1han2 and HIV-1sf13
strains. In the second study, all immunized animals were rechallenged
with SHIV89.6p, a virus closely related to the vaccine
strain but highly virulent. Protection from either of the divergent
SHIVsf13 or SHIVhan2 challenges was
demonstrated in the majority of the vaccinated animals. In contrast,
upon challenge with the more related but virulent
SHIV89.6p, protection was achieved in only one of the previously protected vaccinees. A secondary but beneficial effect of
immunization on virus load and CD4+ T-cell counts was
observed despite failure to protect from infection. In addition to
revealing different levels of protective immunity, these results
suggest the importance of developing vaccine strategies capable of
protecting from particularly virulent variants of HIV-1.
*
Corresponding author. Mailing address: Biomedical
Primate Research Center, Department of Virology, P.O. Box 3306, 2280 GH Rijswijk, The Netherlands. Phone: 31 152842661. Fax: 31 152843986. E-mail: heeney{at}bprc.nl.
Journal of Virology, May 2000, p. 4017-4027, Vol. 74, No. 9
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Mooij, P., Balla-Jhagjhoorsingh, S. S., Koopman, G., Beenhakker, N., van Haaften, P., Baak, I., Nieuwenhuis, I. G., Kondova, I., Wagner, R., Wolf, H., Gomez, C. E., Najera, J. L., Jimenez, V., Esteban, M., Heeney, J. L.
(2008). Differential CD4+ versus CD8+ T-Cell Responses Elicited by Different Poxvirus-Based Human Immunodeficiency Virus Type 1 Vaccine Candidates Provide Comparable Efficacies in Primates. J. Virol.
82: 2975-2988
[Abstract]
[Full Text]
-
Koopman, G., Mortier, D., Hofman, S., Mathy, N., Koutsoukos, M., Ertl, P., Overend, P., van Wely, C., Thomsen, L. L., Wahren, B., Voss, G., Heeney, J. L.
(2008). Immune-response profiles induced by human immunodeficiency virus type 1 vaccine DNA, protein or mixed-modality immunization: increased protection from pathogenic simian human immunodeficiency virus viraemia with protein/DNA combination. J. Gen. Virol.
89: 540-5533
[Abstract]
[Full Text]
-
Haaft, P. t., Verschoor, E. J., Verstrepen, B., Niphuis, H., Dubbes, R., Koornstra, W., Bogers, W., Rosenwirth, B., Heeney, J. L.
(2004). Readily acquired secondary infections of human and simian immunodeficiency viruses following single intravenous exposure in non-human primates. J. Gen. Virol.
85: 3735-3745
[Abstract]
[Full Text]
-
Mooij, P., Nieuwenhuis, I. G., Knoop, C. J., Doms, R. W., Bogers, W. M. J. M., ten Haaft, P. J. F., Niphuis, H., Koornstra, W., Bieler, K., Kostler, J., Morein, B., Cafaro, A., Ensoli, B., Wagner, R., Heeney, J. L.
(2004). Qualitative T-Helper Responses to Multiple Viral Antigens Correlate with Vaccine-Induced Immunity to Simian/Human Immunodeficiency Virus Infection. J. Virol.
78: 3333-3342
[Abstract]
[Full Text]
-
Pistello, M., Matteucci, D., Bonci, F., Isola, P., Mazzetti, P., Zaccaro, L., Merico, A., Del Mauro, D., Flynn, N., Bendinelli, M.
(2003). AIDS Vaccination Studies Using an Ex Vivo Feline Immunodeficiency Virus Model: Protection from an Intraclade Challenge Administered Systemically or Mucosally by an Attenuated Vaccine. J. Virol.
77: 10740-10750
[Abstract]
[Full Text]
-
Reza, S. M., Shen, L.-M., Mukhopadhyay, R., Rosetti, M., Pe'ery, T., Mathews, M. B.
(2003). A Naturally Occurring Substitution in Human Immunodeficiency Virus Tat Increases Expression of the Viral Genome. J. Virol.
77: 8602-8606
[Abstract]
[Full Text]
-
Voss, G., Manson, K., Montefiori, D., Watkins, D. I., Heeney, J., Wyand, M., Cohen, J., Bruck, C.
(2002). Prevention of Disease Induced by a Partially Heterologous AIDS Virus in Rhesus Monkeys by Using an Adjuvanted Multicomponent Protein Vaccine. J. Virol.
77: 1049-1058
[Abstract]
[Full Text]
-
Horton, H., Vogel, T. U., Carter, D. K., Vielhuber, K., Fuller, D. H., Shipley, T., Fuller, J. T., Kunstman, K. J., Sutter, G., Montefiori, D. C., Erfle, V., Desrosiers, R. C., Wilson, N., Picker, L. J., Wolinsky, S. M., Wang, C., Allison, D. B., Watkins, D. I.
(2002). Immunization of Rhesus Macaques with a DNA Prime/Modified Vaccinia Virus Ankara Boost Regimen Induces Broad Simian Immunodeficiency Virus (SIV)-Specific T-Cell Responses and Reduces Initial Viral Replication but Does Not Prevent Disease Progression following Challenge with Pathogenic SIVmac239. J. Virol.
76: 7187-7202
[Abstract]
[Full Text]
-
Novitsky, V., Smith, U. R., Gilbert, P., McLane, M. F., Chigwedere, P., Williamson, C., Ndung'u, T., Klein, I., Chang, S. Y., Peter, T., Thior, I., Foley, B. T., Gaolekwe, S., Rybak, N., Gaseitsiwe, S., Vannberg, F., Marlink, R., Lee, T. H., Essex, M.
(2002). Human Immunodeficiency Virus Type 1 Subtype C Molecular Phylogeny: Consensus Sequence for an AIDS Vaccine Design?. J. Virol.
76: 5435-5451
[Abstract]
[Full Text]